Teva- Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical company that operates across innovative medicines, generic drugs, biosimilars, and API manufacturing. The company's innovative portfolio is anchored by three key brands: AUSTEDO (deutetrabenazine) for tardive dyskinesia and Huntington's disease chorea, AJOVY (fremanezumab) for migraine prevention, and UZEDY (risperidone) for schizophrenia. Teva maintains one of the world's largest generic pharmaceutical businesses, dispensing approximately 237 million prescriptions annually in the U.S. alone, and is building a growing biosimilar portfolio targeting 18 products. The company operates through three geographic segments — United States, Europe, and International Markets (covering 35+ countries) — along with Other Activities including its Anda U.S. distribution business and third-party API sales. Teva's late-stage pipeline includes ecopipam (EBS-101) for Tourette syndrome, olanzapine LAI for schizophrenia, TEV-408 (anti-IL-15) for vitiligo, and duvakitug (anti-TL1A, developed with Sanofi) for inflammatory bowel diseases and additional indications. The company is executing a multi-year 'Pivot to Growth' strategy focused on expanding innovative and biosimilar medicines, sustaining its generics powerhouse, and achieving organizational transformation with a target of 30% non-GAAP operating income margin by 2027. Teva carries total debt of $16.6 billion and net debt of $12.9 billion, and is transitioning from an ADS program to direct ordinary share listing on the NYSE in September 2026. Updated Jul 29, 2026